

## **Section 5 Title: The Referral Pathway: A Collaborative Approach**

**Author: Marie Tsaloumas**

### **References**

1. Macular degeneration (age-related)- ranibizumab and pegaptanib: Final appraisal determination. 2008. Available from:  
<http://www.nice.org.uk/nicemedia/pdf/TA155guidance.pdf> [Accessed 15 January 2009]
2. Ranibizumab 10mg/ml solution for intravitreal injection (No. 381/07). Available from:  
[http://www.scottishmedicines.org.uk/smc/files/ranibizumab\\_10mgmlsolution\\_intravitrealinjection\\_Lucentis\\_38107.pdf](http://www.scottishmedicines.org.uk/smc/files/ranibizumab_10mgmlsolution_intravitrealinjection_Lucentis_38107.pdf) [Accessed 15 January 2009]
3. RCOphth Commissioning contemporary AMD services: a guide for commissioners and clinicians. 2007. Available from:  
<http://www.rcophth.ac.uk/docs/publications/published-guidelines/CommissionContempAMDServicesV3Final.pdf> [Accessed 15 January 2009]
4. TA68 Macular degeneration (age related) - photodynamic therapy: Guidance. 2003. Available from:  
[http://www.nice.org.uk/nicemedia/pdf/68\\_PDTGuidance.pdf](http://www.nice.org.uk/nicemedia/pdf/68_PDTGuidance.pdf) [Accessed 15 January 2009]

5. Lucentis SPC. Available from:

<http://www.emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=19409> [Accessed 15 January 2009]

6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al.

Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* 2006; 355(14):1419-1431.